Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase

Chronic myelogenous leukemia (CML) is characterized by the oncogenic fusion protein, BCR-ABL protein kinase, against which clinically useful inhibitors have been developed. An alternative approach to treat CML is to degrade the BCR-ABL protein. Recently, potent degraders against BCR-ABL have been de...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibata, Norihito, Shimokawa, Kenichiro, Nagai, Katsunori, Ohoka, Nobumichi, Hattori, Takayuki, Miyamoto, Naoki, Ujikawa, Osamu, Sameshima, Tomoya, Nara, Hiroshi, Cho, Nobuo, Naito, Mikihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131351/
https://www.ncbi.nlm.nih.gov/pubmed/30202081
http://dx.doi.org/10.1038/s41598-018-31913-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131351/
https://www.ncbi.nlm.nih.gov/pubmed/30202081
http://dx.doi.org/10.1038/s41598-018-31913-5

Ejemplares similares